Deutsche Bank on Abbvie (ABBV): 'IMS/IQVIA data for the week ending 8/30/24 show branded Humira holding at 69.6% share (-0.8% w/w) of Adalimumab scripts'
Tweet Send to a Friend
Deutsche Bank analyst James Shin reiterated a Hold rating and $175.00 price target on Abbvie (NYSE: ABBV).The analyst comments "IMS/IQVIA ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
